Analysis of Naturally Occurring Resistance-Associated Variants to NS3/4A Protein Inhibitors, NS5A Protein Inhibitors, and NS5B Polymerase Inhibitors in Patients With Chronic Hepatitis C

The first NS3/4A hepatitis C virus (HCV) protease inhibitors telaprevir and boceprevir were approved in 2011, and both NS5A and NS5B polymerase inhibitors were launched. Recently, direct-acting antivirals (DAAs) have had a major impact on patients infected with HCV. HCV DAAs are highly effective ant...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Gene Expr
Egile Nagusiak: Sun, Danhui, Dai, Mingjia, Shen, Shanshan, Li, Chunyang, Yan, Xuebing
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Cognizant Communication Corporation 2018
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5885147/
https://ncbi.nlm.nih.gov/pubmed/29221500
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3727/105221617X15100607143377
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak